Northwire Canada EditionSaturday, July 11, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Financings Routine +

Alzai Health Corp. Files Final Prospectus in Connection With Initial Public Offering

Alzai Health Files Final Prospectus for $4M Best-Efforts IPO

By The Northwire Desk — AI Analysis Apr 22, 2026 · 16:17 ALZI
Executive Summary
  • Alzai Health Corp. has filed a final long-form prospectus to launch an Initial Public Offering (IPO) on the TSXV.
  • The offering consists of up to 10,000,000 units priced at $0.40 per unit.
  • Gross proceeds are targeted between $3,200,000 and $4,000,000.
  • Net proceeds will be allocated to research and development, sales and marketing, and general working capital.
  • Each unit includes one common share and one-half of a common share purchase warrant.
  • Warrants have an exercise price of $0.60 and expire 24 months from the closing date.
  • Haywood Securities Inc. is acting as the exclusive agent on a best-efforts basis with a 7% commission.
  • Closing and trading commencement are expected around May 21, 2026.
Material Impact
  • The filing represents a standard procedural milestone for an IPO rather than a fundamental business breakthrough.
  • Proceeds of $3.2M to $4.0M are modest for a healthcare company, suggesting limited runway without further financing.
  • Best-efforts structure indicates potential lack of strong institutional demand, which is a risk factor compared to firm-commitment underwritings.
  • The offering price ($0.40) sets the initial market valuation baseline; any premium depends on post-listing performance.
  • Warrant terms (50% upside trigger at $0.60) create potential dilution pressure if the stock rallies significantly within 24 months.
  • No strategic investors or anchor commitments are disclosed in this release, reducing confidence in immediate liquidity support.
ALZI · Price
Company Overview
  • Company Name: Alzai Health Corp.
  • Sector: Healthcare / Biotechnology (specific therapeutic focus not detailed in this prospectus summary).
  • Development Stage: Pre-revenue, seeking capital for R&D and commercialization.
  • Flagship Project: Details regarding specific assets or therapies are not explicitly outlined in the provided news text; investors must refer to the full prospectus for pipeline specifics.
  • Management Background: Not disclosed in this release; due diligence required on executive track record from full filing.
Read the original news release →

More from

Jun 09, 2026 · 08:23

Early-stage AI diagnostics IPO raises $4M to fund Alzheimer's screening R&D and commercialization.

Financings Jun 05, 2026 · 16:15

AI-driven Alzheimer's screening startup prepares for TSXV debut

Financings